- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Do | Eli Lilly beats Novo to oral China GLP-1RA market on NMPA approval | ||
| Do | Blackstone backs Pfizer's obesity ambitions with $1.5bn fund | ||
| Do | Beyond GLP-1RA's: Novel mechanisms and combos to shape future of obesity market | ||
| Do | FDA and EMA waive paediatric studies for Shanton's gout candidate | ||
| Do | Life-extending peptides are likely not around the corner | ||
| Do | Litmys and PharmaACE partner on pharma commercial forecasting | ||
| Mi | AstraZeneca acquires bacterial vaccine biotech, Omniose | ||
| Mi | Longevity sector ambitions outpace regulatory and investment frameworks | ||
| Mi | Moderna's CEO eyes Keytruda-eclipsing future for personalised cancer vaccine | ||
| Mi | ProBio signs global antibody licensing deal with AbTis | ||
| Mi | Lilly-backed Oyster Therapeutics raises $60m for neurological degraders | ||
| Di | VC funding in Europe falls short at early-stage investment hurdles | ||
| Di | Pentagon drops WuXi AppTec from Chinese military company list | ||
| Di | China's burgeoning novel medicines success presents opportunity for Europe | ||
| Di | Delix Therapeutics raises $100m for zalsupindole development | ||
| Di | Charles River agrees $470m deal for Frontage assets | ||
| Mo | Network Bio partners with Duke University on AI disease models | ||
| Mo | Bio-Thera gains Chinese approval for spondylitis and rheumatoid arthritis drug | ||
| 06.11. | FDA expands J&J's Rybrevant Faspro label with head and neck cancer approval | ||
| 06.11. | MHRA champions patient voices through new policy | ||
| 06.11. | Armada to combine with Brains Bioceutical in $750m deal | ||
| 06.11. | Alfasigma receives EC's expanded approval for filgotinib to treat axSpA | ||
| 05.11. | Cordavis to stay in CVS Health after bifurcation of $117bn empire | ||
| 05.11. | Big pharma-backed T-Therapeutics snags $133m to bring TCEs to clinic | ||
| 05.11. | Evommune signs $1.1bn licence deal with Hinova for EVO570 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.